2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters
2021 warning letter rate could decline further
Executive Summary
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.
You may also be interested in...
Chinese Firm Hit With Pandemic's First Remote-Records-Based FDA Drug GMP Warning Letter
Import alert and warning letter came after Ningbo, China, over-the-counter skin care products firm failed to share requested testing records.
Pandemic Will Limit Role Of US FDA Inspections In Driving FY 2021 Drug GMP Sanctions
Look for alternative approaches like sample testing, remote records review and reliance on trusted host nation authorities to fill many inspection gaps – except for OAI re-inspections. Meanwhile, post-emergency planning begins.
Deadly COVID-19 Hand Sanitizer Production Surge Prompted US FDA's New Import Alert Category
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.